JPS62292718A - 経口製剤 - Google Patents
経口製剤Info
- Publication number
- JPS62292718A JPS62292718A JP61135561A JP13556186A JPS62292718A JP S62292718 A JPS62292718 A JP S62292718A JP 61135561 A JP61135561 A JP 61135561A JP 13556186 A JP13556186 A JP 13556186A JP S62292718 A JPS62292718 A JP S62292718A
- Authority
- JP
- Japan
- Prior art keywords
- ibuprofen
- magnesium stearate
- magnesium
- formulation
- lactose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 8
- 229940079593 drug Drugs 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 title abstract description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 38
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229960001680 ibuprofen Drugs 0.000 claims abstract description 28
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 abstract description 24
- 239000000843 powder Substances 0.000 abstract description 7
- 239000002775 capsule Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 239000008187 granular material Substances 0.000 abstract description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052749 magnesium Inorganic materials 0.000 abstract description 3
- 239000011777 magnesium Substances 0.000 abstract description 3
- 208000025865 Ulcer Diseases 0.000 abstract description 2
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- 239000002221 antipyretic Substances 0.000 abstract description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract description 2
- 239000006187 pill Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- -1 troche Substances 0.000 abstract description 2
- 229940125716 antipyretic agent Drugs 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000004503 fine granule Substances 0.000 abstract 1
- 235000019260 propionic acid Nutrition 0.000 abstract 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 abstract 1
- 230000036269 ulceration Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 12
- 239000008101 lactose Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 7
- 229920002678 cellulose Polymers 0.000 description 7
- 239000007963 capsule composition Substances 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical class CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Chemical class CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61135561A JPS62292718A (ja) | 1986-06-11 | 1986-06-11 | 経口製剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61135561A JPS62292718A (ja) | 1986-06-11 | 1986-06-11 | 経口製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62292718A true JPS62292718A (ja) | 1987-12-19 |
| JPH0560810B2 JPH0560810B2 (de) | 1993-09-03 |
Family
ID=15154688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61135561A Granted JPS62292718A (ja) | 1986-06-11 | 1986-06-11 | 経口製剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62292718A (de) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5409709A (en) * | 1991-11-29 | 1995-04-25 | Lion Corporation | Antipyretic analgesic preparation containing ibuprofen |
| JP2005035995A (ja) * | 2003-07-01 | 2005-02-10 | Sankyo Co Ltd | イブプロフェン含有経口用組成物 |
| JP2011052023A (ja) * | 2003-07-01 | 2011-03-17 | Daiichi Sankyo Healthcare Co Ltd | イブプロフェン含有経口用組成物 |
| AT511581A1 (de) * | 2011-05-26 | 2012-12-15 | G L Pharma Gmbh | Orale retardierende formulierung |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56154416A (en) * | 1980-04-30 | 1981-11-30 | Kaken Pharmaceut Co Ltd | Antipyretic analgesic composition |
-
1986
- 1986-06-11 JP JP61135561A patent/JPS62292718A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56154416A (en) * | 1980-04-30 | 1981-11-30 | Kaken Pharmaceut Co Ltd | Antipyretic analgesic composition |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5409709A (en) * | 1991-11-29 | 1995-04-25 | Lion Corporation | Antipyretic analgesic preparation containing ibuprofen |
| JP2005035995A (ja) * | 2003-07-01 | 2005-02-10 | Sankyo Co Ltd | イブプロフェン含有経口用組成物 |
| JP2011052023A (ja) * | 2003-07-01 | 2011-03-17 | Daiichi Sankyo Healthcare Co Ltd | イブプロフェン含有経口用組成物 |
| AT511581A1 (de) * | 2011-05-26 | 2012-12-15 | G L Pharma Gmbh | Orale retardierende formulierung |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0560810B2 (de) | 1993-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200323776A1 (en) | Diclofenac formulations and methods of use | |
| JP3180350B2 (ja) | β―ラクタム系抗生物質含有錠剤およびその製造法 | |
| IE48879B1 (en) | An analgesic effervescent powder and process for its preparation | |
| JPH07112973B2 (ja) | イブプロフェン又はその塩を活物質とする可溶性の消炎性組成物及びその製造方法 | |
| JPH05505193A (ja) | 薬剤製剤 | |
| JPH0717866A (ja) | 医薬組成物 | |
| JP2879905B2 (ja) | イブプロフェン含有経口投与用組成物 | |
| JPS62292718A (ja) | 経口製剤 | |
| TWI286072B (en) | Sleeping medicine formed by coating solid | |
| PT85871B (en) | Process for the preparation of orally administrable pharmaceutical compositions which contain chenodeoxycholic acid or deoxycholic acid or a salt of either of these acids any of wich may be used alone or is combination with a synergist | |
| FI89240C (fi) | Anvaendning av tillsatsmedel foer oekning av ibuprofens absorptionshastighet | |
| JPS63107933A (ja) | シヨ糖硫酸エステルアルミニウム塩製剤の製造法 | |
| IE883560L (en) | Tetracycline tablet | |
| JPS6357521A (ja) | 経口製剤 | |
| JP3947244B2 (ja) | 消化性潰瘍治療用製剤 | |
| JP3202775B2 (ja) | 固形製剤 | |
| JPH1045580A (ja) | 塩化カルニチン含有製剤の製造方法 | |
| WO2003070217A1 (en) | Levothyroxine compositions and methods | |
| JPH02206A (ja) | エキシホンと水溶性高分子化合物とを含有することを特徴とする新規製剤 | |
| JPH09309829A (ja) | ニトレンジピン含有経口投与製剤およびその製造法 | |
| CA2174538A1 (en) | Base for sustained-release preparation, sustained-release preparation, and process for producing the preparation | |
| JPS6360926A (ja) | 感冒薬 | |
| JPH02207A (ja) | 塩酸ブロムヘキシン含有製剤 | |
| JPH0129169B2 (de) | ||
| WO1996025158A1 (fr) | Composition a base de derives de l'azulene et son procede d'obtention |